Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Adalimumab is commercially available as a solution for injection (Humira). It was approved in the United States in 2002 and in many countries and the EU in 2003. Biosimilars are available in many countries. Structure and properties Adalimumab is a human IgG1 monoclonal antibody against TNF-alpha. It is composed of 1330 amino acids and … Adalimumab Effects and Side Effects
Products Bezlotoxumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Zinplava). Structure and properties Bezlotoxumab (ATC J06BB21) is an IgG1 monoclonal antibody with a molecular weight of 148.2 kDa. It is produced by biotechnological methods. Effects Bezlotoxumab … Bezlotoxumab
Products Aducanumab has been studied in phase III trials and is in the pre-approval phase. The drug is not yet commercially available. The trials were discontinued in March 2019. However, following a re-analysis, the company announced in October 2019 that it expected to file for approval. Apparently, a sufficiently high dose is required for an … Aducanumab
